不列颠哥伦比亚省浆母细胞性淋巴瘤的临床病理特征与长期结局
该研究回顾了加拿大不列颠哥伦比亚省1997至2019年间确诊的42例浆母细胞性淋巴瘤患者,其中15例(36%)HIV阳性、9例(21%)长期免疫抑制。31例接受以环磷酰胺、多柔比星、长春新碱和泼尼松为主的根治性治疗,74%获得缓解但61%在中位7.5个月后复发。全队列5年无进展生存率和总生存率分别为18%和22%,生存结局差,需进一步研究更有效治疗策略。
要点
- 42例浆母细胞性淋巴瘤患者中15例(36%)HIV阳性、9例(21%)长期免疫抑制。
- 31例接受根治性治疗,74%缓解,但61%在中位7.5个月后复发。
- 全队列5年无进展生存率18%、总生存率22%,中位分别为8和15个月。
核心结论
- 在这项跨越20年的基于人群的浆母细胞性淋巴瘤队列中,生存结局差,最终需要进一步研究以开发更有效的治疗策略并改善患者生存。
研究设计与样本
- 回顾性分析了加拿大不列颠哥伦比亚省1997年至2019年间所有组织学确诊的浆母细胞性淋巴瘤患者,共识别42例。
主要发现
- 42例患者中15例(36%)HIV阳性,9例(21%)长期免疫抑制。
- 31例接受以环磷酰胺、多柔比星、长春新碱和泼尼松为主的根治性治疗,其中74%获得缓解,但61%在中位7.5个月后复发。
- 全队列中位随访8年,5年无进展生存率为18%(95%CI:6%,30%),5年总生存率为22%(95%CI:8%,36%),中位无进展生存期和总生存期分别为8个月和15个月。
- 按免疫状态分层,复发率(p=0.962)、无进展生存(p=0.228)和总生存(p=0.340)均无差异。
- 接受根治性治疗者,5年无进展生存率为24%(95%CI:8%,40%),5年总生存率为31%(95%CI:13%,49%),中位无进展生存期和总生存期分别为18个月和27个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Plasmablastic lymphoma (PBL) is an aggressive and rare subtype of non-Hodgkin lymphoma with no standard-of-care therapy. We reviewed all patients diagnosed with histologically confirmed PBL in British Columbia, Canada between 1997 and 2019. Overall, 42 patients were identified, including 15 (36%) positive for HIV and nine (21%) on chronic immunosuppression. Curative-intent treatment consisting primarily of cyclophosphamide, doxorubicin, vincristine and prednisone was administered to 31 patients, of which 74% achieved response, however 61% relapsed after a median of 7.5 months. At a median follow-up of eight years for the whole cohort, five-year progression-free survival (PFS) and overall survival (OS) were 18% [95% confidence interval (CI): 6%, 30%] and 22% (95% CI: 8%, 36%) with median eight and 15 months respectively. There were no differences in relapse rate (p = 0.962), PFS (p = 0.228) or OS (p = 0.340) according to immune status. For those treated with curative intent, five-year PFS and OS were 24% (95% CI: 8%, 40%) and 31% (95% CI: 13%, 49%) with median 18 and 27 months respectively. In this population-based cohort of PBL patients spanning 20 years, survival outcomes were poor. Ultimately, further research is needed to develop more effective treatment strategies and to improve survival for patients.
引用
- Jessa R, Chien N, Villa D, et al. Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia. Br J Haematol. 2022. PMID: 35961783. doi:10.1111/bjh.18399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。